Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 68 countries around the world. CytoSorb® is helping to treat life-threatening conditions in the intensive care unit and cardiac surgery. One major application is the reduction of cytokine storm, with the goal of reducing severe inflammation and serious complications such as organ failure—the leading cause of death in the ICU today, while improving patient outcomes and reducing overall costs of critical care. Another newer application is the reduction of antithrombotic agents, often called “blood thinners,” during open heart surgery, with the goal of reducing unwanted perioperative bleeding.
“There were many factors that led to our selection of CytoSorb® for the Global Product Leadership Award,” said Frost & Sullivan Research Analyst Aish Vivek. “Among the most important was the recognition that this innovative product is surprisingly well-positioned to help solve two long-standing, difficult, and tightly linked fundamental problems with hospital medicine today. These include the high rates of death from common critical illnesses such as sepsis that have no approved treatment, and the resulting staggering costs and losses in critical care that are financially crippling hospital networks and healthcare systems throughout the world.”
Analyst Vivek continued, “Further strengthening CytoSorb’s position is the scarcity of viable competition in the lucrative and vast global critical care and cardiac surgery markets, the strong physician usage and revenue growth, and the external validation from well-respected industry partners, such as Fresenius Medical Care and Terumo Cardiovascular, and government funding agencies. As a high margin, single-use product that works with existing blood pumps in hospitals, CytoSorb® also has an attractive business model that is expected to drive early and significant profitability of the company.”
As CytoSorbents expands its footprint worldwide, it is also pursuing U.S. approval of its technologies through two different clinical trials in cardiac surgery. The first is the pivotal REFRESH 2-AKI registration trial that is currently underway, designed to demonstrate a reduction in post-operative kidney injury after high-risk cardiac surgery. The second is the pivotal STAR-T trial, under the auspices of FDA Breakthrough Designation, to remove the blockbuster drug, ticagrelor, and perioperative bleeding risk, during urgent and emergent cardiothoracic surgery.
CytoSorbents aims to be in the elite company of fast growing medical device companies, with rapid growth, industry leading product gross margins in excess of 80%, and GAAP profitability in the near future, with a ground-breaking therapy that can help to save lives.
CytoSorbents is covered by 7 analysts from Cowen & Co., SVB Leerink, Jefferies, H.C. Wainwright, B. Riley, Dawson James, and Maxim, and is part of the Russell 2000 and 3000 Indexes. The Company is led by an experienced and capable management team focused on growth and increasing shareholder value.
- CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
- CytoSorbents Reports Second Quarter 2022 Financial and Operational Results
- CytoSorbents to Report Second Quarter 2022 Operating and Financial Results
- The 2022 CytoSorb World Users' Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Therapeutic Approach
- Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimension in Blood Purification